We interviewed GraniteShares' CEO Will Rhind from New York, soon after they launched a suite of ETP's which allow you to invest in three different baskets of giant US tech stocks. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'
AIM IP specialist Tekcapital to sell or float all four portfolio companies 'within 2 years'View Video
GraniteShares making investing in US tech stock giants easier with innovative FAANG ETP
GraniteShares making investing in US tech stock giants easier with innovative FAANG ETPView Video

Latest Share Chat

Johnson & Johnson to start human safety trial for Covid-19 vaccine

Thu, 30th Jul 2020 12:49

(Sharecast News) - Johnson & Johnson on Thursday started human safety trials for its Covid-19 vaccine after releasing potentially promising details of a study on macaque monkeys.
The vaccine, which has received $456m in funding from the US government, is its best-performing candidate and the study showed that it offers strong protection with just a single dose.

The best-performing vaccine candidate, which J&J selected for human testing, caused all six of the six animals tested to have no sign of the virus in their lungs and only one showed low levels of virus in nasal swabs. Lab tests showed they all had developed antibodies capable of neutralizing the virus after a single shot.

"This gives us confidence that we can test a single-shot vaccine in this epidemic and learn whether it has a protective effect in humans," Paul Stoffels, J&J's chief scientific officer, told Reuters in a telephone interview.

Stoffels said prior tests of this type of vaccine in other diseases found that a second shot significantly increases protection, but the company is seeking a one dose treatment if possible. J&J said it will decide on the dosage in the phase 1 trial.

The company will then begin two parallel phase 3 studies in late September where it will test single and two-shot regimens of the vaccine.

J&J shares were up nearly 2% at $149.72 before the market open on Thursday.

More News

FOREX-Dollar slides to more than two-month low after big U.S. jobs miss

* Nonfarm payrolls rose by 266,000 jobs vs forecast of 978,000* Dollar down broadly* MSCI EM currency index hits record high* Graphic: World FX rates https://tmsnrt.rs/2RBWI5E (Adds reaction to U.S. jobs data, analysts' comments, updates prices, c...

Today 15:04

Watch out for hackers, Britain's spy agency tells smart cities

By Umberto BacchiMay 7 (Thomson Reuters Foundation) - Cities embracing technology to improve urban life risk falling prey to hackers, Britain's cyber security agency warned on Friday, urging local authorities to ensure smart cities are armed with ...

Today 15:03

COLUMN-Lead and zinc miss out on the supercycle party: Andy Home

(The opinions expressed here are those of the author, a columnist for Reuters.)* LME metals relative performance: https://tmsnrt.rs/3uuTQeh* ILZSG zinc market balances: https://tmsnrt.rs/3nVl9Mk* ILZSG lead market balances: https://tmsnrt.rs/3nTNKSn...

Today 14:58

IN BRIEF: Thesolia sells 16% stake in Star Phoenix to Preceding Max

IN BRIEF: Thesolia sells 16% stake in Star Phoenix to Preceding Max

Today 14:56

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.